ChemoMetec Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Martin Behrens

Chief executive officer

DKK 2.9m

Total compensation

CEO salary percentage	30.0%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	3.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Martin Behrens's remuneration changed compared to ChemoMetec's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	DKK 3m	DKK 877k	DKK 136m

Compensation vs Market: Martin's total compensation ($USD412.53K) is below average for companies of similar size in the German market ($USD1.42M).

Compensation vs Earnings: Insufficient data to compare Martin's compensation with company performance.

CEO

Martin Behrens (32 yo)

less than a year

Tenure

DKK 2,923,041

Compensation

Mr. Martin Helbo Behrens serves as CEO at ChemoMetec A/S since March 13, 2024. He is Chief Operating Officer of ChemoMetec A/S from December 2023. He was Vice Chief Operating Officer of ChemoMetec A/S from...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Martin Behrens	CEO & COO	less than a year	DKK 2.92m	no data
Hans Glensbjerg	Deputy Chairman & Senior Advisor	no data	DKK 150.00k	0.31% € 3.3m
Kim Nicolajsen	Chief Financial Officer	less than a year	no data	no data
Christopher Runchel	Chief Sales Officer	no data	no data	no data
Marta Planaguma	Chief Marketing & Strategy Officer	less than a year	no data	no data
Lisbet Helles	Head of Marketing	less than a year	no data	no data
Søren Kjærulff	Head of R&D	no data	no data	no data
Bo Nielsen	Chief R&D Officer and Physicist & Project Manager	less than a year	no data	no data

0.9yrs

Average Tenure

44yo

Average Age

Experienced Management: CHY's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Hans Glensbjerg	Deputy Chairman & Senior Advisor	no data	DKK 150.00k	0.31% € 3.3m
Peter Reich	Independent Director	10.1yrs	DKK 100.00k	0.0083% € 87.0k
Kristine Faerch	Independent Director	4.1yrs	DKK 100.00k	0.00032% € 3.3k
Niels Thestrup	Chairman	3.1yrs	DKK 360.00k	0.011% € 117.0k
Betina Hagerup	Independent Director	3.1yrs	DKK 100.00k	0.0017% € 17.6k

3.6yrs

Average Tenure

62yo

Average Age

Experienced Board: CHY's board of directors are considered experienced (3.6 years average tenure).

ChemoMetec Management

Management criteria checks 2/4

Key information

Recent management updates

Deputy Chairman & Senior Advisor recently bought €428k worth of stock

Insufficient new directors

ChemoMetec A/S Announces CFO Changes

ChemoMetec A/S Announces CEO Changes

ChemoMetec A/S Announces Executive Changes

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Recent updates

Deputy Chairman & Senior Advisor recently bought €428k worth of stock

Investor sentiment improves as stock rises 27%

Now 52% overvalued after recent price rise

ChemoMetec A/S Maintains Earnings Guidance for the Full-Year 2024-2025

Insufficient new directors

ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA.

Investor sentiment improves as stock rises 23%

ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025

ChemoMetec A/S Approves Dividend

Upcoming dividend of kr.4.00 per share

ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA.

Dividend of kr.4.00 announced

Full year 2024 earnings released: EPS: kr.7.83 (vs kr.10.27 in FY 2023)

ChemoMetec A/S provides earnings guidance for the year 2024/25

ChemoMetec A/S to Report Fiscal Year 2025 Results on Sep 11, 2025

Investor sentiment improves as stock rises 20%

ChemoMetec A/S Announces CFO Changes

Investor sentiment improves as stock rises 15%

Now 24% overvalued

Investor sentiment deteriorates as stock falls 19%

ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24

Investor sentiment deteriorates as stock falls 17%

ChemoMetec A/S Announces CEO Changes

Investor sentiment improves as stock rises 32%

First half 2024 earnings released: EPS: kr.4.05 (vs kr.6.06 in 1H 2023)

ChemoMetec A/S Maintains Earnings Guidance for the Year 2024

ChemoMetec A/S Announces Executive Changes

Investor sentiment improves as stock rises 22%

Investor sentiment improves as stock rises 27%

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 15%

Upcoming dividend of kr.6.00 per share at 1.8% yield

Chemometec A/S Proposes Dividend for the 2022/23 Financial Year

Full year 2023 earnings released: EPS: kr.10.27 (vs kr.9.16 in FY 2022)

New minor risk - Financial data availability

ChemoMetec A/S to Report Fiscal Year 2024 Results on Sep 11, 2024

ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 25%

First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022)

ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023

Investor sentiment deteriorated over the past week

Chemometec A/S Announces Resignation of Steen Søndergaard as CEO

Less than half of directors are independent

ChemoMetec A/S Provides Earnings Guidance for the Financial Year 2022-23

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021)

ChemoMetec A/S Provides Revenue Guidance for the Fiscal Year 2023

ChemoMetec A/S, Annual General Meeting, Oct 12, 2023

Less than half of directors are independent

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of kr.4.00 per share

Full year 2021 earnings released: EPS kr.5.08 (vs kr.3.51 in FY 2020)

New 90-day high: €80.40

First half 2021 earnings released: EPS kr.2.43 (vs kr.1.68 in 1H 2020)

New 90-day high: €76.60

New 90-day high: €66.30

New 90-day high: €60.70

Full year earnings released - EPS €3.51

New 90-day high: €54.00

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure